Zacks Investment Research upgraded shares of Valeant Pharmaceuticals (VRX) from UNDERPERFORM to OUTPERFORM on October 31, 2014, with a target price of $158.00.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Valeant Pharmaceuticals (VRX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment